Choo Jovin J Y, Vet Laura J, McMillan Christopher L D, Harrison Jessica J, Scott Connor A P, Depelsenaire Alexandra C I, Fernando Germain J P, Watterson Daniel, Hall Roy A, Young Paul R, Hobson-Peters Jody, Muller David A
Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.
Vaxxas Pty Ltd, Translational Research Institute, Brisbane, QLD, Australia.
NPJ Vaccines. 2021 May 7;6(1):66. doi: 10.1038/s41541-021-00328-1.
Dengue viruses (DENV) cause an estimated 390 million infections globally. With no dengue-specific therapeutic treatment currently available, vaccination is the most promising strategy for its control. A wide range of DENV vaccines are in development, with one having already been licensed, albeit with limited distribution. We investigated the immunogenicity and protective efficacy of a chimeric virus vaccine candidate based on the insect-specific flavivirus, Binjari virus (BinJV), displaying the structural prM/E proteins of DENV (BinJ/DENV2-prME). In this study, we immunized AG129 mice with BinJ/DENV2-prME via a needle-free, high-density microarray patch (HD-MAP) delivery system. Immunization with a single, 1 µg dose of BinJ/DENV2-prME delivered via the HD-MAPs resulted in enhanced kinetics of neutralizing antibody induction when compared to needle delivery and complete protection against mortality upon virus challenge in the AG129 DENV mouse model.
登革病毒（DENV）在全球范围内估计导致3.9亿人感染。由于目前尚无针对登革热的特异性治疗方法，疫苗接种是控制该病最有前景的策略。多种登革病毒疫苗正在研发中，其中一种已获许可，尽管其分发范围有限。我们研究了一种基于昆虫特异性黄病毒宾贾里病毒（BinJV）的嵌合病毒候选疫苗的免疫原性和保护效力，该疫苗展示登革病毒的结构蛋白prM/E（BinJ/DENV2-prME）。在本研究中，我们通过无针高密度微阵列贴片（HD-MAP）递送系统用BinJ/DENV2-prME免疫AG129小鼠。与针头注射相比，通过HD-MAPs递送单剂量1μg的BinJ/DENV2-prME进行免疫可增强中和抗体诱导动力学，并在AG129登革病毒小鼠模型中提供完全的病毒攻击致死保护。
Zotero 插件
